Cancer Research Institute (CRI)

From a baseball game at Nationals Park, to a visit to the Capital Wheel or to the United States Naval Academy, discover 10 ways you can make the most of your time in and around the greater Washington, D.C. area, while attending #CICON24 this September: https://bit.ly/4eN9lG0 #CancerResearch #Immunotherapy #CICON

How could a discovery in the gut microbiome offer a roadmap for immunotherapy? New research from investigators at Gustave Roussy demonstrates that the ratio of specific microbial communities in the gut can help to predict who will respond to checkpoint inhibitors. CRI Scientific Advisory Council member Dr. Jennifer Wargo of MD Anderson Cancer Center describes how these insights provide assistance in answering "why the search for a single gut microbe that could boost responses to cancer immunotherapy was so challenging. Instead of focusing on individual microbial species, the work shows that the overall make-up of microbial communities in the gut influences a person’s response. 'It’s all about the community structure,' Dr. Wargo says." More: https://lnkd.in/eFzuvn8B #Microbiome #CancerResearch #Immunotherapy #GutMicrobiome

Thank you for your support during Cancer Immunotherapy Month! Together, we’ve unlocked our $300,000 match. Your gift will be in the hands of CRI scientists in the next 30 days, enabling them to continue making advancements in immunotherapy research with new technologies including AI, machine learning, and bioinformatics. As a member of CRI's powerful community, each one of you is making a difference by funding innovative cancer research, bringing us closer to creating a world #Immune2Cancer.

Fuel the future of cancer research, and give more hope to patients everywhere by donating during June's Cancer Immunotherapy Month! Give today for a world immune to cancer, and double your impact now. Your donation will be matched up to $300,000 by a group of generous donors only until June 30, 2024: https://bit.ly/44MjRZz #CancerResearch #Immunotherapy #Immune2Cancer

"I was diagnosed on December 22, 2014, with stage four non-small cell lung cancer," shares Terry. "I'm still here! That's the bottom line." Hear how an immunotherapy clinical trial offered her hope, and understand how it ultimately transformed Terry's life: https://bit.ly/3zdZvN9 #CancerResearch #Immunotherapy #ClinicalTrial #Immune2Cancer

According to a recent article in The New York Times, re-evaluations of past studies have uncovered overlooked truths: alcohol, in any amount, is detrimental to our health. Researchers believe that drinking seven alcoholic beverages a week could cost us about two and a half months of our lifespan, and consuming five or more drinks daily could reduce our lifespan by over two years. Understand how you can weigh the health risks of alcohol consumption, in order to make informed decisions about your drinking habits, in our new blog: https://bit.ly/4clntES #CancerResearch #CancerRisk

Show your support as #TeamCRI fundraiser Omar Ghaffar takes on a record-breaking challenge today, to benefit lifesaving cancer immunotherapy research! With a goal of completing 700 holes, Omar will try to set the record for the most indoor golf holes played in 24 hours, a title which currently sits at 666 holes. Make a gift to DriveOutCancer24 today: https://bit.ly/4ehUfrN #CancerResearch #Immunotherapy #CommunityFundraising

Today, Genmab announced that the FDA has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This approval makes EPKINLY "the first and only T cell engaging bispecific antibody administered subcutaneously approved in the United States to treat this patient population." Learn more: https://bit.ly/45JUo3t #Lymphoma #CancerResearch #FDAApproval

Don't miss out! It's your last chance to place your bids in the Cancer Research Institute Associate Board's silent auction! Explore rare offerings, and make your bids now on vintage jewelry, exceptional wines, autographed sports memorabilia, a golf outing, and more, to benefit the CRI Irvington Postdoctoral Fellowship Program: https://bit.ly/3wxvKG3 #CancerResearch #Immune2Cancer #SilentAuction

Despite progress in the research and treatment of non-small cell lung cancer (NSCLC) over the past decade, most patients are still being diagnosed after their cancer has advanced and data is lacking across many patient populations. In this STAT News article, CRI’s CEO and Director of Scientific Affairs, Dr. Jill O'Donnell-Tormey, highlights results of our recent survey with Regeneron on research areas that U.S. oncologists would like to prioritize to potentially improve the lives of these patients. Read more at the link.